We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Genetic Test Aims to Shorten Brain Tumor Diagnosis Time

By LabMedica International staff writers
Posted on 29 Sep 2026

Brain tumors can be highly aggressive and difficult to treat, and The Brain Tumour Charity describes them as the biggest cancer killer of children and adults under 40. More...

With more than 100 recognized tumor types, accurate classification is critical for guiding treatment decisions. New findings now show that an ultra-rapid genetic test could reduce the time needed for diagnosis from weeks to just hours.

Newcastle University, working with Newcastle Hospitals, is one of five specialist centers in a new U.K. network of excellence evaluating the brain tumor test. The approach uses nanopore genetic sequencing and software known as ROBIN to analyze tumor DNA. Scientists and doctors will act as early adopters while gathering further evidence on the test’s effectiveness in adults and children with brain tumors.

The two-year project will assess whether the rapid test is suitable for wider NHS use. It will examine whether the approach benefits patients, provides clinicians with useful information, and works reliably in health care settings. The Newcastle team includes specialists in genetics, tissue-based disease diagnosis, cancer, and neurology.

Current diagnostic workflows require tumor samples taken during surgery to be sent to specialist laboratories for detailed analysis. Although highly accurate, this process can take several weeks to confirm the exact tumor type. The new single-test approach is intended to generate results much faster than traditional methods and could provide a more complete diagnostic profile within days.

The project follows an initial Newcastle Hospitals Charity-funded project that used the test on 40 different types of brain tumors from children, young people, and adults across the northeast. The team’s longer-term aspiration is to obtain a provisional result while the patient is still in surgery. The work is intended to build on findings already demonstrated through a national pilot program.

“This is really exciting. The test could revolutionize brain tumor diagnosis. At the moment we carry out different genetic tests which can take a few weeks to provide a complete set of results. This new single test could give us all the information that we require for brain tumor diagnosis within days,” said Angharad Goodman, clinical scientist at the Newcastle Genetics Laboratory.

Related Links
Newcastle University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Automated Urinalysis Solution
UN-9000
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Lead author Professor Chamindie Punyadeera. (Image Credit: Griffith University)

Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules

Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.